Clinical Trials Logo

Malignant Neoplasms clinical trials

View clinical trials related to Malignant Neoplasms.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT04881981 Not yet recruiting - Malignant Neoplasms Clinical Trials

A Phase I Study Evaluating the Safety of Stereotactic Central Ablative Radiation Therapy (SCART) for Bulky Metastatic or Recurrent Cancer

Start date: June 5, 2021
Phase: Phase 1
Study type: Interventional

We aim to evaluate the feasibility and toxicity of testing the tolerance and immunogenic effects of high-dose SCART radiotherapy in patients with bulky metastatic or recurrent cancer in the setting of a single-arm phase I clinical trial. The primary endpoint of the study was to determine dose-limiting toxicities (DLT)s and the Maximum Tolerated Dose (MTD) of SCART to bulky metastatic or recurrent cancers.

NCT ID: NCT04202848 Not yet recruiting - Breast Cancer Clinical Trials

The Clinical Study of Modern Therapies on Flora in Body Fluids and Blood of Malignant Tumor Patients

Start date: December 20, 2019
Phase:
Study type: Observational

The clinical study of modern therapies on flora changing in blood, oral cavity, urethra and intestinal tract of patients with malignant tumors. The study is observational. Patients are diagnosed cancer based on pathology or cell biology. The sample of flora will be obtained from their blood, oral cavity, urethra and intestinal tract, mainly to study what modern therapies lead to the influence of microecological environment including diversity and abundance of bacteria in patients who received malignant tumors. Immunological examination and Blood biochemistry evaluation include the number ratio, activity and function of immune cell, the immune cell marker(CD3, CD4, CD8, etc), C-reactive protein(CRP), tumor necrosis factor(TNF), Inflammatory stimulant factor(IL-2, IL-6, etc), tumor marker(CEA, AFP, etc),etc. Clinical evaluation includes image data(CT/MRI), quality of life(QOL), no disease progression survival, total survival, objective disease remission rate, etc.